{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:59:02Z","timestamp":1793973542424,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["2019R1A2C4070136"],"award-info":[{"award-number":["2019R1A2C4070136"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ejim.2021.02.019","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T12:53:55Z","timestamp":1617195235000},"page":"48-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus\u2013related hepatocellular carcinoma"],"prefix":"10.1016","volume":"89","author":[{"given":"Ji Hyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beom Kyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1914-5141","authenticated-orcid":false,"given":"Won Young","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Sinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-8050","authenticated-orcid":false,"given":"Seung Up","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2021.02.019_bib0001","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3350\/cmh.2018.0106","article-title":"Unmet need in chronic hepatitis B management","volume":"25","author":"Liang","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0002","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2021.02.019_bib0003","doi-asserted-by":"crossref","first-page":"e00140","DOI":"10.14309\/ctg.0000000000000140","article-title":"Natural History of Untreated HBeAg-Positive Chronic HBV Infection With Persistently Elevated HBV DNA but Normal Alanine Aminotransferase","volume":"11","author":"Lee","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3350\/cmh.2017.0112","article-title":"Epidemiology of liver cancer in South Korea","volume":"24","author":"Kim","year":"2018","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0005","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0006","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0007","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/2012.jama.11975","article-title":"Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection","volume":"308","author":"Wu","year":"2012","journal-title":"JAMA - Journal of the American Medical Association"},{"key":"10.1016\/j.ejim.2021.02.019_bib0008","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0009","doi-asserted-by":"crossref","first-page":"e00036","DOI":"10.14309\/ctg.0000000000000036","article-title":"Prognosis of Untreated Minimally Active Chronic Hepatitis B Patients in Comparison With Virological Responders by Antivirals","volume":"10","author":"Lee","year":"2019","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0010","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0011","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0012","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/hepr.12584","article-title":"Adjuvant antiviral therapy for hepatitis B virus-related hepatocellular carcinoma after curative treatment: A systematic review and meta-analysis","volume":"46","author":"Liu","year":"2016","journal-title":"Hepatology Research"},{"key":"10.1016\/j.ejim.2021.02.019_bib0013","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1245\/s10434-009-0694-z","article-title":"A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection","volume":"17","author":"Li","year":"2010","journal-title":"Annals of Surgical Oncology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0014","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2169\/internalmedicine.48.1534","article-title":"Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function","volume":"48","author":"Koda","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.ejim.2021.02.019_bib0015","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea","volume":"71","author":"Kim","year":"2019","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0016","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/jvh.12971","article-title":"Mortality, liver transplantation and hepatic complications in patients with treatment-na\u00efve chronic hepatitis B treated with entecavir vs tenofovir","volume":"25","author":"Kim","year":"2018","journal-title":"Journal of viral hepatitis"},{"key":"10.1016\/j.ejim.2021.02.019_bib0017","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijid.2014.09.004","article-title":"Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naive patients with chronic hepatitis B: a multicenter real-life study","volume":"28","author":"Batirel","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ejim.2021.02.019_bib0018","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/hepr.12902","article-title":"Randomized prospective study showing the non-inferiority of tenofovir to entecavir in treatment-naive chronic hepatitis B patients","volume":"48","author":"Koike","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ejim.2021.02.019_bib0019","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2019.05.017","article-title":"Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other?","volume":"71","author":"Wong","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0020","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA oncology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(20)30673-5","article-title":"Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection","author":"Choi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0022","doi-asserted-by":"crossref","first-page":"93","DOI":"10.3350\/cmh.2019.1002","article-title":"KASL clinical practice guidelines for management of chronic hepatitis B","volume":"25","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0023","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cgh.2019.05.004","article-title":"Alcoholic and Nonalcoholic Fatty Liver Disease and Incident Hospitalization for Liver and Cardiovascular Diseases","volume":"18","author":"Chang","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0024","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1503\/cjs.028410","article-title":"Results of en bloc resection for hepatocellular carcinoma extending to adjacent organs","volume":"55","author":"Zhou","year":"2012","journal-title":"Can J Surg"},{"key":"10.1016\/j.ejim.2021.02.019_bib0025","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3350\/cmh.2018.0096","article-title":"Appropriate treatment modality for solitary small hepatocellular carcinoma: Radiofrequency ablation vs. resection vs. transplantation?","volume":"25","author":"Ahn","year":"2019","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0026","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1002\/cam4.2417","article-title":"Development and validation of a prognostic model for patients with hepatocellular carcinoma undergoing radiofrequency ablation","volume":"8","author":"Kim","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejim.2021.02.019_bib0027","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3348\/kjr.2019.0140","article-title":"2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma","volume":"20","year":"2019","journal-title":"Korean J Radiol"},{"key":"10.1016\/j.ejim.2021.02.019_bib0028","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1053\/j.gastro.2019.11.314","article-title":"Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B","volume":"158","author":"Lee","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0029","article-title":"Re: Tenofovir vs. Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma after Surgical Resection","author":"Kim","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0030","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1055-9965.EPI-19-0614","article-title":"Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study","volume":"29","author":"Kim","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ejim.2021.02.019_bib0031","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000096313","article-title":"Molecular epidemiology of hepatitis B virus (HBV) genotypes and serotypes in patients with chronic HBV infection in Korea","volume":"50","author":"Kim","year":"2007","journal-title":"Intervirology"},{"key":"10.1016\/j.ejim.2021.02.019_bib0032","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3851\/IMP1982","article-title":"HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B","volume":"16","author":"Kim","year":"2011","journal-title":"Antiviral therapy"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521000777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620521000777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:34:51Z","timestamp":1760607291000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620521000777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":32,"alternative-id":["S0953620521000777"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2021.02.019","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus\u2013related hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2021.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}